(E)-3-[3-methyl-2-[1-[(9-methylspiro[7,8-dihydro-6H-carbazole-5,1'-cyclohexane]-2-carbonyl)amino]cyclobutyl]benzimidazol-5-yl]prop-2-enoic acid | 1488285-44-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (E)-3-[3-methyl-2-[1-[(9-methylspiro[7,8-dihydro-6H-carbazole-5,1'-cyclohexane]-2-carbonyl)amino]cyclobutyl]benzimidazol-5-yl]prop-2-enoic acid
• CAS: 1488285-44-4
• 化学式: C₃₄H₃₈N₄O₃
• 分子量: 550.701
• InChiKey: CSXSBZMJYDEKSC-GXDHUFHOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.5
• 重原子数：
  41
• 可旋转键数：
  5
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  89.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-环己烯基乙酸 在 吡啶 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 lithium aluminium tetrahydride 、 水 、 碘 、 sodium hydride 、 二乙胺 、 三乙胺 、 三苯基膦 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium iodide 、 potassium hydroxide 、 sodium hydroxide 、 palladium dichloride 作用下， 以 乙醚 、 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 、 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 、 乙腈 为溶剂， 生成 (E)-3-[3-methyl-2-[1-[(9-methylspiro[7,8-dihydro-6H-carbazole-5,1'-cyclohexane]-2-carbonyl)amino]cyclobutyl]benzimidazol-5-yl]prop-2-enoic acid
  参考文献：
  名称：

  Conformation-Based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127)

  摘要：

  Conformational restrictions of flexible torsion angles were used to guide the identification of new chemotypes of HCV NS5B inhibitors. Sites for rigidification were based on an acquired conformational understanding of compound binding requirements and the roles of substituents in the free and bound states. Chemical bioisosteres of amide bonds were explored to improve cell-based potency. Examples are shown, including the design concept that led to the discovery of the phase III clinical candidate deleobuvir (BI 207127). The structure-based strategies employed have general utility in drug design.

  DOI：

  10.1021/jm4011862

文献信息

• Conformation-Based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127)
  作者：Steven R. LaPlante、Michael Bös、Christian Brochu、Catherine Chabot、René Coulombe、James R. Gillard、Araz Jakalian、Martin Poirier、Jean Rancourt、Timothy Stammers、Bounkham Thavonekham、Pierre L. Beaulieu、George Kukolj、Youla S. Tsantrizos

  DOI：10.1021/jm4011862

  日期：2014.3.13

  Conformational restrictions of flexible torsion angles were used to guide the identification of new chemotypes of HCV NS5B inhibitors. Sites for rigidification were based on an acquired conformational understanding of compound binding requirements and the roles of substituents in the free and bound states. Chemical bioisosteres of amide bonds were explored to improve cell-based potency. Examples are shown, including the design concept that led to the discovery of the phase III clinical candidate deleobuvir (BI 207127). The structure-based strategies employed have general utility in drug design.